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Pulmonary hypertensionAbstract Pulmonary arterial hypertension is defined as a group of diseases characterized by a pro-
gressive increase in pulmonary vascular resistance, leading to right ventricular failure and prema-
ture death. Pathobiologic mechanisms of the disease include pulmonary endothelial dysfunction,
which leads to impaired production of vasodilators, such as nitric oxide and prostacyclin, and over-
expression of vasoconstrictors, such as endothelin-1.
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine
monophosphate, thereby enhancing the cyclic guanosine monophosphate-mediated relaxation
and growth inhibition of vascular smooth-muscle cells, including those in the lung.
Methods: In this prospective study 139 patients with symptomatic pulmonary arterial hyperten-
sion (2ry to COPD) received placebo or sildenafil (20 mg) orally three times daily for 12 weeks. The
end point was the change from baseline to week 12 in the distance walked in six minutes. The
change in mean pulmonary-artery pressure and the incidence of clinical worsening were also
assessed, but the study was not powered to assess mortality.
Results: The distance walked in six minutes increased from baseline in sildenafil group; the mean
placebo-corrected treatment effects were 51 m (+13.0 percent), for 20 mg of sildenafil, (P< 0.001).
Sildenafil dose reduced the mean pulmonary-artery pressure (P= 0.04), and was associated with
side effects such as flushing, dyspepsia, and diarrhea. The incidence of clinical worsening did not
differ significantly between the patients treated with sildenafil and those treated with placebo.
Conclusion: Sildenafil improves exercise capacity, and hemodynamic in patients with symp-
tomatic pulmonary arterial hypertension.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Pulmonary arterial hypertension is defined as a group of
diseases characterized by a progressive increase in pulmonary
806 K. Alkhayat, M. Eidvascular resistance, leading to right ventricular failure and pre-
mature death [1,2]. Pathobiologic mechanism of the disease
includes pulmonary endothelial dysfunction, which leads to
impaired production of vasodilators, such as nitric oxide and
prostacyclin, and overexpression of vasoconstrictors, such as
endothelin-1 [3,4].
Treatment includes conventional agents (anticoagulants,
diuretics, digoxin, and supplemental oxygen, as well as
calcium-channel blockers in selected patients), vasodilators,
and antiproliferative agents such as prostanoids and
endothelin-receptor antagonists, which are targeted at abnor-
malities of endothelial function [5,6]. Four agents are currently
approved for the treatment of pulmonary arterial hypertension
in the United States and Europe: intravenous epoprostenol,
the inhaled prostacyclin analog iloprost, the subcutaneously
and intravenously administered prostacyclin analog trepros-
tinil, and the oral endothelin-receptor antagonist bosentan.
Although these drugs are efficacious, adverse effects in terms
of safety, tolerability, drug delivery, or all of these factors
occur with all of these agents [5,6]. In addition, some medical
therapy may fail in some patients in which case they may be
considered for lung transplantation [7].
Changes in nitric oxide pathways have been detected in
patients with pulmonary arterial hypertension, and although
inhaled nitric oxide is used for testing acute vasoreactivity,
the long-term administration of this agent is cumbersome
and requires a complex delivery system [8,9].
The pulmonary vasodilating effects of nitric oxide are
mediated through its second messenger, cyclic guanosine
monophosphate (cGMP), which is rapidly degraded by phos-
phodiesterase. Phosphodiesterase type 5 is the predominant
phosphodiesterase isoform in the lung that metabolizes cGMP,
and it has been shown to be up-regulated in conditions associ-
ated with pulmonary hypertension. By selectively inhibiting
phosphodiesterase type 5, sildenafil citrate (Revatio, Pfizer)
promotes the accumulation of intracellular cGMP and thereby
enhances nitric oxide-mediated vasodilatation; it may also
have antiproliferative effects on pulmonary vascular smooth-
muscle cells. Initial studies involving animal models, data from
open label, uncontrolled trials involving patients with
pulmonary arterial hypertension, and a small randomized,
controlled study involving patients with idiopathic pulmonary
arterial hypertension suggest that sildenafil is beneficial in the
treatment of pulmonary arterial hypertension [10,11].
The objectives of our trial were to assess the efficacy and
tolerability of sildenafil 20 mg given orally three times
daily in patients with secondary pulmonary arterial
hypertension.
Selection of patients
Patients were included if they had pulmonary arterial hyper-
tension (2ry to COPD). Pulmonary arterial hypertension was
defined as a mean pulmonary-artery pressure of 25 mm Hg
or more as measured indirectly by echocardiography Study,
medication was added to the patient’s conventional therapy.
Treatment with intravenous epoprostenol, oral bosentan,
intravenous or inhaled iloprost, or subcutaneous treprostinil
and supplementation with L-arginine were prohibited. Patients
with a six-minute walking distance of less than 100 m or more
than 450 m were excluded.Echocardiographic assessment
The diagnosis of pulmonary arterial hypertension depends on
direct measurement of the mean PAP by right heart catheteri-
zation but in our study we measured PAP indirectly by
echocardiography. Echocardiography can provide an estimate
of the pulmonary artery systolic pressure (PASP). PASP was
determined by measuring the peak systolic pressure gradient
from the right ventricle to the right atrium. This was calculated
using the modified Bernoulli equation: 4v2, where v is the max-
imum velocity of the tricuspid valve regurgitant jet, measured
by continuous wave Doppler, added to the estimated right
atrial pressure. The following formula was derived to estimate
mean PAP: mean PAP = 0.65 PASP + 0.55 mmHg.
Study design
Prospective study was done for 12-weeks, from January 2015
and January 2016. Patients were classified into two groups:
1st (69) patients received sildenafil 20 mg 3 times daily for
12 weeks and 2nd group received placebo. All patients received
the conventional therapy for COPD. Echocardiography was
done for all patients for diagnosis of pulmonary hypertension
and every 4 weeks as a follow up. Baseline walking distance in
six minutes was done at first then every 4 weeks.
Outcome measures
The primary measure of efficacy was the change in exercise
capacity, as measured by the total distance walked in six min-
utes, from baseline to week 12. Other measures of efficacy were
the changes in mean pulmonary-artery pressure, and time from
study to clinical worsening (defined as death, transplantation,
hospitalization for pulmonary arterial hypertension, or initia-
tion of additional therapies for pulmonary arterial hyperten-
sion, such as intravenous epoprostenol or oral bosentan).
Physical examinations and laboratory tests were performed,
and investigators recorded adverse events throughout study.
Statistical analysis
The primary end point was evaluated with the use of a sequen-
tial step-down, closed testing procedure, in which the mean
response in group receiving sildenafil was compared with that
in the placebo group. All pair wise comparisons for the pri-
mary end point were carried out at the prespecified two sided
alpha level of 0.01 with the use of a two-samplet-test, stratified
for baseline walking distance. Assuming that there was a treat-
ment effect from sildenafil of 51 m, as compared with placebo,
and a standard deviation of 75 m. Mean pulmonary-artery
pressure was analyzed with the use of a stratified t-test; the
time to clinical worsening was analyzed with the use of a strat-
ified log-rank test (data for patients with no documentation of
clinical worsening were included in the analysis as censored
observations); and the mean pulmonary-artery pressure, a
patient must have received the study drug and had both a base-
line and at least one post-baseline measurement of the specific
end point. To be included in the intention-to-treat analysis for
time to clinical worsening, a patient must have received the
study drug (see Table 1).
Table 1 Baseline characteristics of the patients.
Character Placebo (70) Sildenafil (69)
Male sex 57 49
Age 49 ± 17 47 ± 14
Walking distance 344 ± 79 347 ± 90
Heart rate 81 ± 16 82 ± 12
Pulmonary arterial pressure 56 ± 16 45 ± 13
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Exercise capacity
An increase in the distance walked in six minutes was observed
in group receiving sildenafil, as compared with placebo, at
week 4, and this effect was maintained at weeks 8 and 12.
The mean placebo-corrected treatment effects among 69
patients at week 12 were 51 m among those receiving 20 mg
of sildenafil (99 Percent Confidence Interval, 21–70;
P< 0.001) (Fig. 1).
Echocardiographic results
The patients receiving sildenafil had decrease from the baseline
value in mean pulmonary-artery pressure. These changes









Figure 1 Mean changes from baseline, with 95 Percent Confidence Int
and sildenafil groups.
Table 2 Mean change in hemodynamic from baseline to week 12.
Variables Placebo
H.R 1.3 (4.1 to 1.4)
Mean pulmonary arterial pressure 0.6 (0.8 to 2.0)
The values shown represent the mean change, P value are for the compaSafety
Most adverse events were mild to moderate in intensity. No
clinically significant changes were seen in any laboratory vari-
ables evaluated. The distribution and incidence of adverse
events were similar among patients with different types of pul-
monary arterial hypertension, and the median times of first
occurrence were clustered within the first four to five weeks
of treatment. No death was judged to be causally related to
the study treatment (Table 3).
In this trial, sildenafil significantly improved exercise capac-
ity, as assessed according to the six-minute walking test, in
patients with pulmonary arterial hypertension secondary to
COPD. Our findings show that there is a symptomatic benefit
associated with the inhibition of phosphodiesterase type 5 in
patients with pulmonary arterial hypertension.
Discussion
In this placebo-controlled trial, sildenafil significantly
improved exercise capacity, as assessed according to the six-
minute walking test, in patients with pulmonary arterial hyper-
tension. Our findings show that there is a symptomatic benefit
associated with the inhibition of phosphodiesterase type 5 in
patients with pulmonary arterial hypertension improvement
in exercise capacity with sildenafil treatment, regardless of
demographic or disease characteristics or other baseline vari-
ables. The study was not designed to assess mortality. The
six-minute walking test is an independent predictor of death
in patients with idiopathic pulmonary arterial hypertension8 12
s
p
ervals, in the six-minute walking distance at week 12 in the placebo
Sildenafil P value
3.7 (5.9 to 1.4) 0.18
2.1 (4.3 to 0.0) 0.04
rison of sildenafil group with placebo.
Table 3 Incidence of the most frequent adverse events in the
placebo and sildenafil group.
Adverse events Placebo Sildenafil
Headache 27 (39) 32 (46)
Flushing 3 (4) 7 (10)
Dyspepsia 5 (7) 9 (13)
Back pain 8 (11) 9 (13)
Diarrhea 4 (6) 6 (9)
Limb pain 4 (6) 5 (7)
Myalgia 3 (4) 5 (7)
Cough 4 (6) 5 (7)
Epistaxis 1 (1) 6 (9)
Pyrexia 2 (3) 4 (6)
Insomnia 1 (1) 5 (7)
Influenza 2 (3) 4 (6)
Visual disturbance 0 0
Gastritis 0 2 (3)
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als involving patients with pulmonary arterial hypertension [5].
The treatment-related increase in walking distance of 50 m
observed in this study is similar to the increases observed with
the use of intravenous epoprostenol (47 m) [13], inhaled ilo-
prost (36 m) [14], and oral bosentan (44 m) [15] and is higher
than the increase seen with the use of subcutaneous treprostinil
(16 m) [16]. Sildenafil also significantly improved cardiopul-
monary hemodynamics in 12 weeks, as compared with
changes in 12 weeks in the placebo group. The reduction in
pulmonary-artery pressure was similar to those observed with
intravenous epoprostenol and oral bosentan in smaller studies.
Hemodynamic variables are related to survival in patients with
idiopathic pulmonary arterial hypertension, and the results of
this study confirm the clinical relevance of the effects of silde-
nafil [17]. It is not clear what mechanisms are involved in the
hemodynamic improvements seen in patients with pulmonary
arterial hypertension who have predominantly fixed pul-
monary vascular obstructive lesions. It has been suggested that
there is possible reverse remodeling of pulmonary vascular
changes with both prostanoids and endothelin-receptor antag-
onists, on the basis of their antiproliferative properties [12],
and this may also explain the effects seen with sildenafil. The
incidence of clinical worsening was not significantly different
in the patients treated with sildenafil than in those treated with
placebo.
However, the overall incidence of clinical worsening in this
study was low and may be related to the short duration of the
study (12 weeks).
Most adverse events were of mild to moderate severity, and
there were no clinically significant changes in laboratory vari-
ables. Complex delivery systems, significant side effects, or
both, are associated with intravenous epoprostenol (e.g.,
catheter-related infections, sepsis, and pump malfunctions),
subcutaneous treprostinil (infusion-site pain), inhaled iloprost
(multiple daily inhalations), and oral bosentan (abnormalities
of hepatic function) [15]. There was no evidence of dose–
response relationship associated with the primary end point
(exercise capacity) or with tolerability in the 12-week study.
The reason for this phenomenon is not clear but may be
related to the complete inhibition of phosphodiesterase type
5 with the lowest dose. Limitations of the study include theexclusion of certain patient populations with pulmonary arte-
rial hypertension, such as patients in whom the
pulmonary arterial hypertension is associated with the human
immunodeficiency virus, patients with portal hypertension,
and those with hypertension that is associated with uncor-
rected congenital systemic to-pulmonary shunts. Additional
studies involving these subgroups of patients are needed.
In conclusion, this study demonstrates the efficacy and
safety of sildenafil in the treatment of patients with symp-
tomatic pulmonary arterial hypertension secondary to COPD.
Our assessment of efficacy was limited to exercise capacity and
Echocardiographic findings, and the study was not designed to
address the important end point of mortality.
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